Loading clinical trials...
Loading clinical trials...
A Subject and Investigator Blinded, Randomized, Placebo-controlled, Repeat-dose, Multicenter Study to Investigate Efficacy, Safety, and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis
Conditions
Interventions
CMK389
Placebo
Locations
22
United States
Novartis Investigative Site
Birmingham, Alabama, United States
Univ of Florida College of Medicine x
Gainesville, Florida, United States
University of Kansas Medical Center
Kansas City, Kansas, United States
John Hopkins Asthma And Alrgy Cntr
Baltimore, Maryland, United States
Icahn School Of Med At Mount Sinai .
New York, New York, United States
East Carolina University .
Greenville, North Carolina, United States
Start Date
September 23, 2020
Primary Completion Date
September 19, 2023
Completion Date
December 12, 2023
Last Updated
April 13, 2025
NCT06169397
NCT06113991
NCT03599414
NCT01587001
NCT01732211
NCT02188017
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions